These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26465375)

  • 1. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
    Gil RJ; Bil J; Grundeken MJ; Iñigo Garcia LA; Vassilev D; Kern A; Pawłowski T; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1246-1254. PubMed ID: 26465375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis.
    Bil J; Gil RJ; Vassilev D; Rzezak J; Kulawik T; Pawlowski T
    J Interv Cardiol; 2014 Jun; 27(3):242-51. PubMed ID: 24708143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
    Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
    J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
    Gil RJ; Bil J; Kern A; Pawłowski T
    Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
    Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
    Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
    Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
    Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
    Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
    Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
    Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis.
    Briguori C; Visconti G; Golino M; Focaccio A; Signoriello G
    Catheter Cardiovasc Interv; 2019 Sep; 94(3):323-331. PubMed ID: 30773807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.
    Gil RJ; Bil J; Kern A; Iñigo Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Segiet A
    Cardiol J; 2018; 25(3):308-316. PubMed ID: 28840591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.
    Gil RJ; Vassilev D; Michalek A; Kern A; Formuszewicz R; Dobrzycki S; Wójcik J; Lesiak M; Kardaszewicz P; Lekston A
    EuroIntervention; 2012 Jul; 8(3):316-24. PubMed ID: 22829507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry.
    Mylotte D; Meftout B; Moynagh A; Vaquerizo B; Darremont O; Silvestri M; Louvard Y; Leymarie JL; Morice MC; Lefèvre T; Garot P
    EuroIntervention; 2012 Dec; 8(8):970-81. PubMed ID: 23014945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry.
    Gil RJ; Kern A; Pawłowski T; Bil J
    Arch Med Sci; 2023; 19(2):324-330. PubMed ID: 37034511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of a dedicated bifurcation stent system.
    Sivalingam J; Mazhar MW; Chaddad RA; Fouladvand F; Cortese B
    Cardiovasc Revasc Med; 2024 Feb; 59():21-26. PubMed ID: 37666716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study.
    Salvatella N; Morice MC; Darremont O; Tafflet M; Garot P; Leymarie JL; Chevalier B; Lefèvre T; Louvard Y; Boudou N; Dumonteil N; Carrié D
    EuroIntervention; 2011 Oct; 7(6):689-96. PubMed ID: 21986327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study.
    Verheye S; Agostoni P; Dubois CL; Dens J; Ormiston J; Worthley S; Trauthen B; Hasegawa T; Koo BK; Fitzgerald PJ; Mehran R; Lansky AJ
    J Am Coll Cardiol; 2009 Mar; 53(12):1031-9. PubMed ID: 19298915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and long-term results of unprotected left main coronary artery stenosis with paclitaxel-eluting stents: the FRIEND (French multicentre RegIstry for stenting of uNprotecteD LMCA stenosis) registry.
    Carrié D; Eltchaninoff H; Lefèvre T; Silvestri M; Brunel P; Fajadet J; Moynagh A; Gilard M; Koning R; Dibie A; Darremont O; Lablanche JM; Blanchard D;
    EuroIntervention; 2011 Oct; 7(6):680-8. PubMed ID: 21986326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.